权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

DCTD Functional Genomics

DCTD功能基因组学

基本信息

批准号：
8429247
负责人：
DAVID HEIMBROOK
金额：
$ 77.25万
依托单位：
LEIDOS BIOMEDICAL RESEARCH, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-26 至 2018-09-25
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8429247
关键词：
Alkaloids Althaea American Association of Cancer Research Animals Area Biological Assay Blood specimen Businesses CCAAT-Enhancer-Binding Proteins CCR CHEK2 gene CHES1 gene Cell Cycle Cell Line Cell surface Cells Cessation of life Clinic Clinical Collaborations Cooperative Research and Development Agreement DNA Damage DNA Repair Data Databases Development Developmental Therapeutics Program Drug Combinations Drug effect disorder European Organization for Research and Treatment of Cancer Evaluation Studies Extramural Activities Gene Expression Genes Genomics Histone Deacetylase Inhibitor Histones Human In Vitro Kinesin Laboratories Laboratory Animals Lead Legal patent Measures Methods Mitosis Modeling Molecular Profiling Molecular Target Oligonucleotide Microarrays PXD101 Paclitaxel Pathway interactions Patients Pattern Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Phase Play Preclinical Drug Development Proteins Publishing RNA RNA Interference Reporter Genes Research Support Resources Role Sampling Scientist Screening procedure Staging Techniques Technology Testing Therapy Evaluation Time Topoisomerase Topotecan Tretinoin Tumor Cell Line Up-Regulation Whole Blood Xenograft procedure analog aurora-A kinase base blood treatment cancer diagnosis cancer therapy cytotoxicity drug development drug discovery functional genomics in vivo inhibitor/antagonist insight marine natural product meetings melanoma neutrophil novel pre-clinical programs protein expression research study response tool tumor vacuolar H+-ATPase

项目摘要

This project is a major part of the Developmental Therapeutics Program drug discovery and development program within the Division of Cancer Treatment and Diagnosis. The emphasis is on preclinical drug discovery and preclinical drug development. LABORATORY OF FUNCTIONAL GENOMICS (LFG) The Laboratory of Functional Genomics (LFG) provides dedicated research support for the Screening Technologies Branch (STB), Developmental Therapeutics Program (DTP), drug discovery and development effort. Genomic techniques, including oligonucleotide microarrays, TaqMan(R) real-time PCR, reporter gene assays, mutiplexing gene assays, and RNAi are used as tools to determine the role of specific genes in the mechanisms of drug action. These methods have provided an important resource to probe for preliminary insights into mechanism of action of novel agents, or detailed analyses with preclinical drugs at a more advanced stage. The laboratory offers a resource for small businesses or extra- and intramural scientists to collaborate in an effort to bring new drugs to the clinic. Moreover, the expertise gained in this area has allowed the laboratory to play a critical role in proposing a large-scale project centered on gene profiling of drug responses in the NCI-60 cell line screen. In addition, the LFG provides preclinical, in vitro drug combination studies for evaluation of possible desirable or undesirable interactions for potential clinical drug combinations, as requested by DTP or the Clinical Therapy Evaluation Program (CTEP).

该项目是癌症治疗和诊断部发展治疗项目药物发现和开发项目的主要组成部分。重点是临床前药物发现和临床前药物开发。